AstraZeneca will invest over 100 billion yuan in China before 2030.

On January 29th, AstraZeneca announced plans to invest over 100 billion RMB in China by 2030 to expand its presence in drug production and research and development. These investments will further deepen AstraZeneca's research and development presence in China, including global strategic research centers in Beijing and Shanghai, which collaborate with over 500 clinical hospitals and have led numerous global clinical trials in the past three years. Additionally, the company will upgrade its production bases in Wuxi, Taizhou, Qingdao, and Beijing, and will announce plans for new production bases in due course. The existing bases are currently supplying high-quality innovative drugs to patients in China and over 70 global markets. Through these investments, AstraZeneca's workforce in China will exceed 20,000 employees, creating thousands of new jobs in the entire healthcare ecosystem.